Common Contracts

81 similar null contracts by Genocea Biosciences, Inc., Proteostasis Therapeutics, Inc., Aircastle LTD, others

Comstock Resources, Inc. 40,000,000 Shares 1 Common Stock ($0.50 par value) Underwriting Agreement
Comstock Resources Inc • May 15th, 2020 • Crude petroleum & natural gas • New York
AutoNDA by SimpleDocs
EX-1.1 2 reta-ex11_6.htm EX-1.1 UNDERWRITING AG Reata Pharmaceuticals, Inc. 3,000,000 Shares Class A Common Stock ($0.001 par value per share) Underwriting Agreement New York, New York July 24, 2018 Jefferies LLC Leerink Partners LLC Stifel, Nicolaus...
New York • May 5th, 2020

Reata Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom Jefferies LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated (together, the “Representatives”) are acting as representatives, 3,000,000 shares of Class A common stock, $0.001 par value per share (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 450,000 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the

Millendo Therapeutics, Inc. 4,166,667 Shares Common Stock ($0.001 par value) Underwriting Agreement
Millendo Therapeutics, Inc. • December 5th, 2019 • Pharmaceutical preparations • New York
Genocea Biosciences, Inc. [·] Shares of Common Stock ($0.001 par value per share) Underwriting Agreement
Genocea Biosciences, Inc. • June 18th, 2019 • Biological products, (no disgnostic substances) • New York
AIRCASTLE LIMITED Underwriting Agreement
Aircastle LTD • June 13th, 2019 • Services-equipment rental & leasing, nec • New York

Aircastle Limited, a company incorporated under the laws of Bermuda (the “Company”), proposes to issue and sell to the several parties named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the principal amount of its securities identified in Schedule I hereto (the “Securities”), to be issued under an indenture, dated as of December 5, 2013 (the “Base Indenture”), as supplemented by the seventh supplemental indenture, to be dated as of June 13, 2019 (the “Supplemental Indenture” and, together with the Base Indenture, the “Indenture”) between the Company and Wells Fargo Bank, National Association, as trustee (the “Trustee”) relating to the issuance of the Securities. To the extent that there are no additional parties listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or the plural as the co

Underwriting Agreement
Applied Therapeutics Inc. • April 29th, 2019 • Pharmaceutical preparations • New York

This press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended.

Dermira, Inc. 9,811,321 Shares Common Stock ($0.001 par value) Underwriting Agreement
Dermira, Inc. • March 20th, 2019 • Pharmaceutical preparations • New York

Dermira, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of common stock, $0.001 par value (“Common Stock”) of the Company set forth on Schedule I hereto (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth on Schedule I hereto (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). Any reference herein to the Registration Statement, the Base Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to

Proteostasis Therapeutics, Inc. 11,000,000 Shares Common Stock (par value $0.001 per share) Underwriting Agreement
Proteostasis Therapeutics, Inc. • October 24th, 2018 • Pharmaceutical preparations • New York

Proteostasis Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 11,000,000 shares of its common stock, par value $0.001 per share (“Common Stock”) (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 1,650,000 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requi

Reata Pharmaceuticals, Inc. 3,000,000 Shares Class A Common Stock ($0.001 par value per share) Underwriting Agreement
Reata Pharmaceuticals Inc • July 26th, 2018 • Pharmaceutical preparations • New York

Reata Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom Jefferies LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated (together, the “Representatives”) are acting as representatives, 3,000,000 shares of Class A common stock, $0.001 par value per share (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 450,000 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the

Translate Bio, Inc. Shares Common Stock ($0.001 par value per share) Underwriting Agreement
Translate Bio, Inc. • June 12th, 2018 • Biological products, (no disgnostic substances) • New York

This press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended.

BrightView Holdings, Inc. [●] Shares Common Stock ($0.01 par value) Underwriting Agreement
BrightView Holdings, Inc. • June 11th, 2018 • Agricultural services • New York

BrightView Holdings, Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [●] shares of common stock, $0.01 par value (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [●] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). Certain terms used herein are defined in Section 21 hereof.

Apellis Pharmaceuticals, Inc. Shares Common Stock ($0.0001 par value per share) Underwriting Agreement
Apellis Pharmaceuticals, Inc. • April 16th, 2018 • Pharmaceutical preparations • New York

Apellis Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [•] shares of common stock, $0.0001 par value per share (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [•] additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires.

Proteostasis Therapeutics, Inc. 8,000,000 Shares Common Stock (par value $0.001 per share) Underwriting Agreement
Proteostasis Therapeutics, Inc. • December 15th, 2017 • Pharmaceutical preparations • New York

Proteostasis Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 8,000,000 shares of its common stock, par value $0.001 per share (“Common Stock”) (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 1,200,000 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requir

Apellis Pharmaceuticals, Inc. Shares Common Stock ($0.0001 par value per share) Underwriting Agreement
Apellis Pharmaceuticals, Inc. • October 20th, 2017 • Pharmaceutical preparations • New York

Apellis Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, shares of common stock, $0.0001 par value per share (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural

Flexion Therapeutics, Inc. 4,800,000 Shares Common Stock ($0.001 par value) Underwriting Agreement
Flexion Therapeutics Inc • October 12th, 2017 • Pharmaceutical preparations • New York

Flexion Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of its common stock, $0.001 par value (“Common Stock”) set forth in Schedule I hereto opposite the heading “Number of Underwritten Securities to be sold by the Company” (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I hereto opposite the heading “Number of Option Securities to be sold by the Company” (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). Any reference herein to the Registration Statement, the

3,250,000 Shares Class A Common Stock ($0.001 par value per share) Underwriting Agreement
Reata Pharmaceuticals Inc • July 28th, 2017 • Pharmaceutical preparations • New York

Reata Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom Jefferies LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated (together, the “Representatives”) are acting as representatives, 3,250,000 shares of Class A common stock, $0.001 par value per share (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 487,500 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the

Gardner Denver Holdings, Inc. 41,300,000 Shares Common Stock ($0.01 par value) Underwriting Agreement
Gardner Denver Holdings, Inc. • May 3rd, 2017 • General industrial machinery & equipment • New York

Gardner Denver Holdings, Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 41,300,000 shares of common stock, $0.01 par value (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 6,195,000 additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). Certain terms used herein are defined in Section 21 hereof.

Uniti Group Inc. 16,981,133 Shares Common Stock ($0.0001 par value) Underwriting Agreement
Uniti Group Inc. • April 25th, 2017 • Real estate investment trusts • New York
Calithera Biosciences, Inc. 6,830,000 Shares Common Stock ($0.0001 par value) Underwriting Agreement
Calithera Biosciences, Inc. • March 22nd, 2017 • Pharmaceutical preparations • New York

Calithera Biosciences, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representative”) are acting as representative, 6,830,000 shares of common stock, $ 0.0001 par value (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 1,024,500 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representative as used herein shall mean you, as Underwriter, and the terms Representative and Underwriters shall mean either the singular or plural as the context requires. Certain terms use

AIRCASTLE LIMITED Underwriting Agreement
Aircastle LTD • March 10th, 2017 • Services-equipment rental & leasing, nec • New York

Aircastle Limited, a company incorporated under the laws of Bermuda (the “Company”), proposes to issue and sell to the several parties named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the principal amount of its securities identified in Schedule I hereto (the “Securities”), to be issued under an indenture, dated as of December 5, 2013 (the “Base Indenture”), as supplemented by the fifth supplemental indenture, to be dated as of March 20, 2017 (the “Supplemental Indenture” and, together with the Base Indenture, the “Indenture”) between the Company and Wells Fargo Bank, National Association, as trustee (the “Trustee”) relating to the issuance of the Securities. To the extent that there are no additional parties listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or the plural as the con

Dermira, Inc. 5,000,000 Shares Common Stock ($0.001 par value) Underwriting Agreement
Dermira, Inc. • March 2nd, 2017 • Pharmaceutical preparations • New York

Dermira, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representative”) are acting as representative, the number of shares of common stock, $0.001 par value (“Common Stock”) of the Company set forth on Schedule I hereto (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth on Schedule I hereto (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representative as used herein shall mean you, as Underwriters, and the term Underwriters shall mean either the singular or

AMC ENTERTAINMENT HOLDINGS, INC. 19,047,619 Shares Class A Common Stock ($0.01 par value) Underwriting Agreement
Amc Entertainment Holdings, Inc. • February 13th, 2017 • Services-motion picture theaters • New York
AutoNDA by SimpleDocs
Flexion Therapeutics, Inc. 3,600,000 Shares Common Stock ($0.001 par value) Underwriting Agreement
Flexion Therapeutics Inc • November 16th, 2016 • Pharmaceutical preparations • New York

Flexion Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of its common stock, $0.001 par value (“Common Stock”) set forth in Schedule I hereto opposite the heading “Number of Underwritten Securities to be sold by the Company” (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I hereto opposite the heading “Number of Option Securities to be sold by the Company” (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters liste

Proteostasis Therapeutics, Inc. [●] Shares Common Stock (par value $0.001 per share) Underwriting Agreement
Proteostasis Therapeutics, Inc. • August 31st, 2016 • Pharmaceutical preparations • New York

Proteostasis Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [●] shares of its common stock, par value $0.001 per share (“Common Stock”) (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [●] additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. Certain

Oncobiologics, Inc. [________] Shares1 Common Stock ($0.01 par value) Underwriting Agreement
Oncobiologics, Inc. • April 27th, 2016 • Biological products, (no disgnostic substances) • New York
Mercury Systems, Inc. 4,500,000 Shares Common Stock ($0.01 par value) plus an option to purchase from the Company up to 675,000 shares of Common Stock Underwriting Agreement
Mercury Systems Inc • April 8th, 2016 • Electronic components & accessories • New York

Mercury Systems, Inc., a corporation organized under the laws of Massachusetts (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of common stock, $0.01 par value (“Common Stock”), of the Company set forth in Schedule I hereto (the “Securities”) (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I hereto (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Unde

Underwriting Agreement
Weatherford International PLC • March 3rd, 2016 • Oil & gas field machinery & equipment • New York

This letter is being delivered to you in connection with the proposed Underwriting Agreement (the “Underwriting Agreement”), by and among Weatherford International public limited company, an Irish public limited company (the “Company”), and each of you as representatives of a group of Underwriters named therein, relating to an underwritten public offering of ordinary shares, par value $0.001 USD per share (the “Ordinary Shares”), of the Company.

Epizyme, Inc. 13,333,334 Shares Common Stock ($0.0001 par value) Underwriting Agreement
Epizyme, Inc. • January 7th, 2016 • Pharmaceutical preparations • New York

Epizyme, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 13,333,334 shares of its common stock, $0.0001 par value (“Common Stock”) (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 2,000,000 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. Certain terms used her

First Data Corporation 160,000,000 Shares Class A Common Stock ($0.01 par value) Underwriting Agreement
First Data Corp • October 1st, 2015 • Services-business services, nec • New York

First Data Corporation, a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 160,000,000 shares of Class A common stock, $0.01 par value (“Class A Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 24,000,000 additional shares of Class A Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). Certain terms used herein are defined in Section 22 hereof.

Genocea Biosciences, Inc. 3,850,000 Shares Common Stock ($0.001 par value) Underwriting Agreement
Genocea Biosciences, Inc. • July 30th, 2015 • Biological products, (no disgnostic substances) • New York

Genocea Biosciences, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 3,850,000 shares of common stock, $0.001 par value (“Common Stock”), of the Company (such shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 577,500 additional shares of Common Stock, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requir

Catabasis Pharmaceuticals, Inc. Shares Common Stock ($0.001 par value per share) Underwriting Agreement
Catabasis Pharmaceuticals Inc • June 11th, 2015 • Pharmaceutical preparations • New York

Catabasis Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, shares of common stock, $0.001 par value per share (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plura

Raptor Pharmaceutical Corp. 9,500,000 Shares Common Stock ($0.001 par value) Underwriting Agreement
Raptor Pharmaceutical Corp • April 3rd, 2015 • Pharmaceutical preparations • New York

Raptor Pharmaceutical Corp., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of common stock, $0.001 par value (“Common Stock”), of the Company set forth in Schedule I hereto (the “Securities”) (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I hereto (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Un

Epizyme, Inc. 6,000,000 Shares Common Stock ($0.0001 par value) Underwriting Agreement
Epizyme, Inc. • March 18th, 2015 • Pharmaceutical preparations • New York

Epizyme, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 6,000,000 shares of its common stock, $0.0001 par value (“Common Stock”) (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 900,000 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. Certain terms used herein

Genocea Biosciences, Inc. 5,454,545 Shares Common Stock ($0.001 par value) Underwriting Agreement
Genocea Biosciences, Inc. • March 12th, 2015 • Biological products, (no disgnostic substances) • New York

Genocea Biosciences, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 5,454,545 shares of common stock, $0.001 par value (“Common Stock”), of the Company (such shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 818,181 additional shares of Common Stock, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requir

AltheaDx, Inc. [—] Shares Common Stock ($0.0001 par value) Underwriting Agreement
AltheaDx, Inc. • January 23rd, 2015 • Services-medical laboratories • New York

AltheaDx, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Citigroup Global Markets Inc. and Jefferies LLC (the “Representatives”) are acting as representatives, [—] shares of common stock, $0.0001 par value (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [—] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singu

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!